Netherlands· NL-c197adb18946

Invokana 100 mg filmomhulde tabletten

A canagliflozin product containing canagliflozine 0,5-water, registered in Netherlands by Janssen-Cilag International NV. The same ATC class is registered in 15 of our 19 countries.

ATC A10BK02

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about canagliflozine 0,5-waterAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Canagliflozin is registered in 15 of 19 countries.

Countries holding a registration under ATC A10BK02 (canagliflozin), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search canagliflozin products by name

Canagliflozin · ATC A10BK02

15 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of canagliflozin costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), the median price runs from $2.52 in Switzerland to $25.50 in United States — a ×10 gap.

3 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown
US figures are pharmacy acquisition cost (CMS NADAC), not retail

Open the full comparison — free account Drug prices for market access

Canagliflozin · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

US United States$25.50 (acquisition cost)
IT Italy$3.76
CH Switzerland$2.52

Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: CANAGLIFLOZINE 0,5-WATER
Manufacturer: Janssen-Cilag International NV
Country: Netherlands (NL)
ATC code: A10BK02
ATC class: Canagliflozin
Defined daily dose: 0.2 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/13/884

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

429 interactions on record for canagliflozin.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check canagliflozin against other medicines How interaction checks work

Canagliflozin · interactions on record

429 records

1 severe
388 moderate
40 minor

Most severe, free to view

SucralfateA02BX02moderate
PapaverineA03AD01moderate
ThiethylperazinA04AB03moderate
TriflupromazinA04AD06moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Canagliflozin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All canagliflozin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Invokana
Liechtenstein · Invokana
Norway · Invokana

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/3f620494-3652-47ec-970b-141141f73dd6
GET /v1/drugs/3f620494-3652-47ec-970b-141141f73dd6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/invokana-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Canagliflozin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp112483",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "HYPROLOSE (E 463)",
    "IJZEROXIDE GEEL (E 172)",
    "LACTOSE 0-WATER",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "CANAGLIFLOZINE 0,5-WATER"
  ],
  "leaflet_url": null,
  "authorised_at": "2013/11/15",
  "procedure_number": "EMEA/H/C/002649",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/13/884",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about canagliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console